Revolution Medicines Doses First Patient In Phase 1/1b Clinical Trial Of RMC-6291, Company's First Mutant-Selective RAS(ON) Inhibitor
Revolution Medicines Doses First Patient In Phase 1/1b Clinical Trial Of RMC-6291, Company's First Mutant-Selective RAS(ON) Inhibitor
革命藥物公司為第一名患者提供RMC-6291的1/1b期臨牀試驗,RMC-6291是該公司第一個突變選擇性RAS(ON)抑制劑
Revolution Medicines Doses First Patient In Phase 1/1b Clinical Trial Of RMC-6291, Company's First Mutant-Selective RAS(ON) Inhibitor
革命藥物公司為第一名患者提供RMC-6291的1/1b期臨牀試驗,RMC-6291是該公司第一個突變選擇性RAS(ON)抑制劑